Correction: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma (Health and Quality of Life Outcomes (2017) 15:247 DOI: 10.1186/s12955-017-0815-5);Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma

Health and Quality of Life Outcomes

Volumn 15, Issue 1, 2017, Pages

  Bharmal, Murtuza ^a   Fofana, Fatoumata ^b   Barbosa, Carla Dias ^c   Williams, Paul ^c   Mahnke, Lisa ^d   Marrel, Alexia ^c   Schlichting, Michael ^a  

^a MERCK KGAA   (Germany)

^b Mapi   (Netherlands)

^c Mapi Patient Centered Outcomes   (France)

^d EMD Serono Research and Development Institute   (United States)

Author keywords

FACT M questionnaire; Merkel cell carcinoma; Patient reported outcomes; Psychometric validation; Quality of life

Indexed keywords

AVELUMAB;

ADULT; AGED; CANCER RADIOTHERAPY; CONCURRENT VALIDITY; CONSTRUCT VALIDITY; CONTENT VALIDITY; CONTROLLED STUDY; CONVERGENT VALIDITY; DIAGNOSTIC VALUE; DISCRIMINANT VALIDITY; EMOTIONALITY; EUROQOL 5D; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY MELANOMA; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MERKEL CELL CARCINOMA; OUTCOME ASSESSMENT; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL IMPACT SCORE; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; REVIEW; SENSITIVITY AND SPECIFICITY; SOCIAL WELFARE; TREATMENT RESPONSE; TUMOR VOLUME; VALIDATION PROCESS; VISUAL ANALOG SCALE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PSYCHOLOGY; QUESTIONNAIRE; REPRODUCIBILITY; STANDARDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES;

EID: 85038947442     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-019-1122-0     Document Type: Erratum

References (30)

1. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832-41.
2. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096-100.
3. Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:2396-403.
4. Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong JH, Zervos EE. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. Am Surg. 2015;81:802-6.
5. Youlden DR, Soyer HP, Youl PH, Fritschi L, Baade PD. Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010. JAMA Dermatol. 2014;150:864-72.
6. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300-9.
7. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, Gilchrist J. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18:2493-9.
8. Santamaria-Barria JA, Boland GM, Yeap BY, Nardi V, Dias-Santagata D, Cusack JC Jr. Merkel cell carcinoma: 30-year experience from a single institution. Ann Surg Oncol. 2013;20:1365-73.
9. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer. 1999;85:2589-95.
10. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-85.
11. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, et al. Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. Washington, DC: In 2017 AACR Annual Meeting; 2017.
12. D'Angelo SP, Russell J, Hassel JC, Lebbe C, Chmielowski B, Rabinowits G, Terheyden P, Brownell I, Zwiener V, Bajars M, et al. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. Chicago: In 2017 ASCO Annual Meeting; 2017.
13. Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health. 2012;15:437-42.
14. US Department of Health and Human Services. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. https://www.fda.gov/downloads/drugsGuidanceComplianceRegulatoyInformation/Guidance/UCM071590.pdf.
15. FDA: Patient-Reported Outcome Measures in U.S. Regulatory Review of Cancer Products. In Workshop on Clinical Outcome Assessments (COAs) in Cancer Clinical Trials; Silver Spring, MD. 2016.
16. Gibbons E, Casanas i Comabella C, Fitzpatrick R. A structured review of patient-reported outcome measures for patients with skin cancer, 2013. Br J Dermatol. 2013;168:1176-86.
17. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire. Cancer. 2008;112:2249-57.
18. Cormier JN, Davidson L, Xing Y, Webster K, Cella D. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol. 2005;3:139-45.
19. Cormier JN, Cromwell KD, Ross MI. Health-related quality of life in patients with melanoma: overview of instruments and outcomes. Dermatol Clin. 2012;30:245-54. viii.
20. Shields AL, Hao Y, Krohe M, Yaworsky A, Mazar I, Foley C, Mehmed F, Globe D. Patient-reported outcomes in oncology drug labeling in the United States: a framework for navigating early challenges. Am Health Drug Benefits. 2016;9:188-97.
21. EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
22. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708-15.
23. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
24. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: the example of health-related quality of life: a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J. 2002;36:209-38.
25. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis. 1987;40:171-8.
26. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:178-89.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
28. Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. Therapeutic Innov Regul Sci. 2016;50(1):22-9.
29. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value Health. 2009;12:1144-50.
30. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.